Elon Musk, RFK Jr., Dr. Oz, and the coming clash over Ozempic

Published On Dec 18, 2024, 10:49 AM

The article discusses a debate among prominent figures such as Elon Musk, RFK Jr., and Dr. Oz regarding the coverage of weight-loss drugs like Ozempic and Wegovy under Medicare. With potential policy changes being considered by the incoming Trump administration, opinions are divided on the drugs' effectiveness and value, which could significantly affect federal spending on obesity treatment. If approved, Medicare's coverage could increase accessibility of these medications, but a clash among political figures over their benefits and costs could influence the outcome of this decision.

Read full article

Stock Forecasts

NVOView NVO chart on TradingView

Positive

If Medicare adopts policies to cover GLP-1 medications like Ozempic for weight loss, it could significantly boost sales for Novo Nordisk. This change may lead to higher revenue and stronger stock performance for the company amidst growing demand for obesity treatments. Thus, the direction appears positive for *NVO*.

Related News

Popular weight-loss drug Wegovy goes on sale in China

Nov 18, 2024, 11:34 PM

There are 180 million people living with obesity in China, who will now be able to purchase the treatment.

NVO

The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?

Nov 16, 2024, 9:00 AM

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

LLY
NVO
AMGN

Weight-loss drug competition heats up with growing pill market

Sep 17, 2024, 5:32 PM

GLP-1 pills are the next frontier for the weight-loss market.

LLY
NVO
PFE